Approval · Notice of Compliance 16439 · 2014
PMS-SUMATRIPTAN: Notice of Compliance 16439
Issued December 17, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16439
- Date
- December 17, 2014
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Change in formulation. alternate maufacturing site for the finished product. revisions to the product monograph
- Therapeutic class
- 5ht1 receptor agonist / migraine therapy
- Canadian reference product
- IMITREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PMS-SUMATRIPTAN | Not yet assigned | — |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 25 MG per TAB
- SUMATRIPTAN 50 MG per TAB
- SUMATRIPTAN 100 MG per TAB